National cancer institute of Canada clinical trials group MAP.3 trial:: Evaluation of exemestane to prevent breast cancer in postmenopausal women

被引：12
|
作者：
Goss, Paul E. [1 ]
Richardson, Harriet [2 ]
Chlebowski, Rowan [3 ]
Johnston, Dianne [2 ]
Sarto, Gloria E. [4 ]
Maunsell, Elizabeth [5 ]
Ingle, James N. [6 ]
Ales-Martinez, Jose E. [7 ]
机构：
[1] Harvard Univ, Sch Med, Boston, MA USA
[2] Queens Univ, Natl Canc Inst, Clin Trials Grp, Kingston, ON K7L 3N6, Canada
[3] Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Torrance, CA 90509 USA
[4] Univ Wisconsin, Sch Med, Madison, WI 53706 USA
[5] Univ Laval, Fac Med, Unite Rech Sante Populat, Quebec City, PQ G1K 7P4, Canada
[6] Mayo Clin, Rochester, MN USA
[7] Hosp Ruber Internacl, Madrid, Spain
来源：
CLINICAL BREAST CANCER | 2007年 / 7卷 / 11期
关键词：
aromatase inhibitors; estrogen receptor; selective estrogen receptor modulators;
D O I：
10.3816/CBC.2007.n.057
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：895 / 900
页数：6
相关论文
共 50 条
  • [41] Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer
    Robarge, Jason D.
    Desta, Zereunesay
    Nguyen, Anne T.
    Li, Lang
    Hertz, Daniel
    Rae, James M.
    Hayes, Daniel F.
    Storniolo, Anna M.
    Stearns, Vered
    Flockhart, David A.
    Skaar, Todd C.
    Henry, N. Lynn
    BREAST CANCER RESEARCH AND TREATMENT, 2017, 161 (03) : 453 - 461
  • [42] Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer
    Jason D. Robarge
    Zereunesay Desta
    Anne T. Nguyen
    Lang Li
    Daniel Hertz
    James M. Rae
    Daniel F. Hayes
    Anna M. Storniolo
    Vered Stearns
    David A. Flockhart
    Todd C. Skaar
    N. Lynn Henry
    Breast Cancer Research and Treatment, 2017, 161 : 453 - 461
  • [43] Phase II Trial of Neoadjuvant Exemestane in Combination With Celecoxib in Postmenopausal Women Who Have Breast Cancer
    Lustberg, Maryam B.
    Povoski, Stephen P.
    Zhao, Weiqiang
    Ziegler, Rebecca M.
    Sugimoto, Yasuro
    Ruppert, Amy S.
    Lehman, Amy M.
    Shiels, Donna R.
    Mrozek, Ewa
    Ramaswamy, Bhuvaneswari
    Layman, Rachel M.
    Brueggemeier, Robert W.
    Shapiro, Charles L.
    CLINICAL BREAST CANCER, 2011, 11 (04) : 221 - 227
  • [44] A phase II study of ZD0473 given as a short infusion every 3 weeks to patients with advanced or metastatic breast cancer: a National Cancer Institute of Canada Clinical Trials Group trial, IND 129
    Gelmon, KA
    Vandenberg, TA
    Panasci, L
    Norris, B
    Crump, M
    Douglas, L
    Walsh, W
    Matthews, SJ
    Seymour, LK
    ANNALS OF ONCOLOGY, 2003, 14 (04) : 543 - 548
  • [45] A phase II study of bortezomib in mantle cell lymphoma: The National Cancer Institute of Canada Clinical Trials Group trial IND.150
    Belch, A.
    Kouroukis, C. T.
    Crump, M.
    Sehn, L.
    Gascoyne, R. D.
    Klasa, R.
    Powers, J.
    Wright, J.
    Eisenhauer, E. A.
    ANNALS OF ONCOLOGY, 2007, 18 (01) : 116 - 121
  • [46] Phase 2 study of T138067-sodium in patients with malignant glioma: Trial of the National Cancer Institute of Canada clinical trials group
    Kirby, S
    Gertler, SZ
    Mason, W
    Watling, C
    Forsyth, P
    Aniagolu, J
    Stagg, R
    Wright, M
    Powers, J
    Eisenhauer, EA
    NEURO-ONCOLOGY, 2005, 7 (02) : 183 - 188
  • [47] Phase I trial of sequential topotecan followed by etoposide in adults with myeloid leukemia: a National Cancer Institute of Canada Clinical Trials Group Study
    M Crump
    J Lipton
    D Hedley
    D Sutton
    F Shepherd
    M Minden
    K Stewart
    S Beare
    E Eisenhauer
    Leukemia, 1999, 13 : 343 - 347
  • [48] Phase I trial of sequential topotecan followed by etoposide in adults with myeloid leukemia: a National Cancer Institute of Canada Clinical Trials Group Study
    Crump, M
    Lipton, J
    Hedley, D
    Sutton, D
    Shepherd, F
    Minden, M
    Stewart, K
    Beare, S
    Eisenhauer, E
    LEUKEMIA, 1999, 13 (03) : 343 - 347
  • [49] MAINTAINING COMPLIANCE IN QUALITY OF LIFE DATA COMPLETION IN CLINICAL TRIALS - THE NATIONAL CANCER INSTITUTE OF CANADA CLINICAL TRIALS GROUP (NCIC CTG) EXPERIENCE
    Bezjak, Andrea
    Palmer, Michael
    Brundage, Michael
    Osoba, David
    Pater, Joseph L.
    QUALITY OF LIFE RESEARCH, 2004, 13 (09) : 1599 - 1599
  • [50] Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: A trial of the National Cancer Institute of Canada-Clinical Trials Group
    Canil, CM
    Moore, MJ
    Winquist, E
    Baetz, T
    Pollak, M
    Chi, KN
    Berry, S
    Ernst, DS
    Douglas, L
    Brundage, M
    Fisher, B
    McKenna, A
    Seymour, L
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (03) : 455 - 460
12345